NCT01714713

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to Two Doses of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects With Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 830 (actual)
• Sponsor: FORUM Pharmaceuticals Inc · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies EVP-6124-015 and EVP-6124-016.

Conditions

• Schizophrenia
• Impaired Cognition

Interventions

Type	Name	Description
DRUG	EVP-6124	Arm 1, 2

Timeline

• Start date: 2013-06-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2012-10-26
• Last updated: 2016-05-03

Locations

128 sites across 16 countries: United States, Argentina, Australia, Belgium, Canada, Colombia, Germany, Italy, Mexico, Poland, Romania, Russia, Singapore, Spain, Ukraine, United Kingdom